NIQ Global Intelligence PLC
Media
NIQ Global Intelligence PLC (NIQ) Stock News
The latest NIQ headlines and market coverage — 4 recent stories, updated throughout the day.
- The Motley Fool·
Is NIQ Global Intelligence Stock a Buy After Its CEO Purchased Shares Worth $1 Million?
NIQ Global Intelligence CEO James Peck purchased 118,625 shares worth approximately $1 million at $8.43 per share on May 18, 2026, signaling bullish sentiment despite the stock declining 55.5% over the prior year. The company reported strong 11% revenue growth in Q1 2026 but swung to an operating loss due to $64.9 million in restructuring costs. With expectations for $70 million in cost savings this year and a price-to-sales ratio below one, the insider buy suggests confidence in future financial improvement.
- Benzinga·
OMNIQ Reports First Quarter 2026 Financial Results
SALT LAKE CITY, May 20, 2026 (GLOBE NEWSWIRE) -- OMNIQ Corp (OTCMTS: OMQS or "OMNIQ" or "the Company") today announced its financial results for the first quarter 2026. The Company reported $7.7 million in quarterly revenue as well as a gross profit increase of 3.3 percent year over year. The Company continues to implement its product focus and cost-reduction strategy designed to increase revenue & footprint, strengthen profitability, and support long-term operational efficiency. Financial Highlights For the three months ended March 31, 2026, compared to the same period in 2025: Revenue was $7.68 million, compared to $7.98 million in the prior-year period. Gross profit increased to $2.255 million, compared to $2.184 million last year. Loss from operations was ($1.2 million), compared to ($425,000) in the prior-year period. Net loss per share improved to ($0.11), compared to ($0.19) last year. Revenue for the three months ended March 31, 2026, was $7.68 million, compared to $7.98 million for the same period in 2025. While revenue was slightly lower year over year, the Company continued to maintain a strong presence across its core markets and strategic deployments, and at the same time continued implementing products focused on serving end customers Gross profit increased to $2.255 million for the quarter, compared to $2.184 million in the prior year period. The improvement reflects continued focus on operational execution, project mix, and higher-margin opportunities across the business. Loss from operations for the quarter was ($1.2 million), compared to ($425,000) in the first quarter of 2025. Operating results reflected continued investments in technology development, operational infrastructure, and strategic business initiatives designed to support future growth. Net loss per share improved to ($0.11) for the three months ended March 31, 2026, compared to ($0.
- GlobeNewswire Inc.·
NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLE
Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.
- Seeking Alpha·Neutral
NIQ and INTAGE Holdings forge strategic sales partnership